RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..8 of 8 - per page
Order by
Ob-X (anti-obesity functional food)
Ob-X is composed of herbal extracts, and reduced body and adipose tissue weight and number and size of lipid vacuoles in the liver in animal studies; reduced body weight, waist circumference and visceral fat in human studies More
Orlistat Capsule/Pharmaceutical formulation with high stability and dissolution and manufacturing process
Disclosed herein are a pharmaceutical formulation with high stability and dissolution, and a method for preparing the pharmaceutical formulation, More
Optimised pulmonary and nasal therapies using supercritical fluid (SCF) particle engineering
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Tackling challenges of poor solubility
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
Stabilisation and rapid reconstitution of biopharmaceuticals
Improving the reconstitution and increasing the stability of biomolecules using supercritical fluid (SCF) processing More
Protein Arginine N-methyltransferase 2 (PRMT-2), a Modulator of NF-kappaB, E2F1, and STAT3 Activity
Methods of modulating PRMT-2 activity or expression in cells More
Novel Benztropine Analogs for Treatment of Cocaine Abuse and Other Mental Disorders
These compounds have demonstrated high affinity and selectivity for the dopamine transporter over other monoamine transponders as well as muscarinic receptors, without a significant cocaine-like behavioral profile. More
Novel Stilbenoid Derivatives and Methods of Their Use
Novel Stilbenoid Derivatives and Methods of Their Use to Modulate Cannabinoid Receptor Activity or Scavenge Reactive Nitrogen Species More
Displaying 1..8 of 8 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Withdrawal of Rimonabant and Sibutramine Create High Unmet Need in Obesity Market
Dec 2010 - 4 pages - $500
Obesity Therapeutics: Understanding market dynamics (presentation)
Apr 2007 - 21 pages - $5,695
Will Anyone Crack the Obesity Drug Market?
Feb 2011 - 102 pages - $2,615
Epidemiology: Obesity – Set to reach pandemic levels as overweight/obese children become adults
Aug 2011 - 60 pages - $5,700
R&D Trends: Obesity - 2006–2011: obesity’s lean years
May 2011 - 40 pages - $3,800
Obesity Drug Markets in the US and EU
Jul 2008 - 148 pages - $3,835
Obesity Market Forecast
Jul 2009 - $15,200
Obesity Therapy Area Pipeline Report
Nov 2010 - 414 pages - $1,495
MarketWatch: Biotechnology
Dec 2008 - 35 pages - $200
Anti-Obesity Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Dec 2010 - 38 pages - $2,000
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us